Independent Proxy Advisory Firms, ISS and Glass Lewis, Recommend ProMIS Shareholders Vote FOR All Proposed Items at the Upcoming Annual and Special Meeting of Shareholders

Alpine Equity Advisors Nicholas Rigopulos, President

 

[PRESSWIRE] TORONTO, Ontario, May 3, 2022 – ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”) is pleased to announce that leading independent proxy advisory firms, Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis & Co. (“Glass Lewis”) have each recommended ProMIS shareholders (“ProMIS Shareholders”) vote “FOR” all the proposed resolutions at the upcoming Annual and Special Meeting of Shareholders (the “Meeting”) to be held on May 12, 2022 at 9:00 am PT.

 

Independent Proxy Advisory Firms, ISS and Glass Lewis, Recommend ProMIS Shareholders Vote FOR All Proposed Items at the Upcoming Annual and Special Meeting of Shareholders

 

The Board of Directors of ProMIS recommends that Shareholders vote in favour of all the proposed items

 

At the Meeting, Shareholders will be asked to elect the board of directors and auditors for the ensuing year, as well as approve amendments to the By-Laws as more particularly described in the Company’s Management Proxy Circular available at www.sedar.com.

 

Independent Third Party Proxy Advisor Recommendations

 

Two leading independent, third-party proxy advisory firms, ISS and Glass Lewis  have both recommended that shareholders vote FOR  all the proposed resolutions.  ISS and Glass Lewis provide proxy voting recommendations to pension funds, investment managers, mutual funds and other institutional shareholders.

 

YOUR VOTE IS IMPORTANT – PLEASE VOTE TODAY

The proxy voting deadline is 9:00 a.m. PT on Tuesday May 10, 2022

 

How to Vote

There are several ways to vote your shares. Due to the essence of time, Shareholders are encouraged to vote online or by telephone.

 

  Beneficial Shareholder                      

Shares held with a broker, bank or other intermediary

Registered Shareholders                           Shares held in own name and represented by a physical certificate
www.proxyvote.com www.investorvote.com
Call or fax to the number(s) listed on your voting instruction form Phone: 1-866-732-8683                                          Fax: 1-866-249-7775
Return the voting instruction form in the enclosed envelope Return the form of proxy in the enclosed postage paid envelope

 

Annual and Special Meeting and Webcast Details

 

ProMIS will hold its Annual and Special Meeting on May 12, 2022 at 9:00 am PT. The Meeting will be held as a virtual only shareholder meeting with participation electronically as explained further in the Management Proxy Circular. As a reminder, proxies must be received by 9:00 am PT on Tuesday, May 10, 2022.

 

Shareholders can participate electronically at https://www.meetnow.global/MZUVNJS. Please see the Management Proxy Circular for detailed instructions on how to access the meeting, vote on resolutions and submit questions. Guests may view the event at https://www.meetnow.global/MZUVNJS by registering as a guest.

 

Please visit the Annual and Special Meeting page on the ProMIS website on the Investor tab for complete details and links to all relevant documents ahead of the Meeting at https://www.promisneurosciences.com/investors/news-events/ir-calendar/detail/8704/annual-general-meeting-2022.

 

ProMIS encourages shareholders to read the Meeting materials, which have been filed on SEDAR (www.sedar.com) and on the Company’s website at https://www.promisneurosciences.com/investors

 

Questions

 

If you have questions about the Meeting matters, the voting instructions or require assistance completing your proxy form, please contact the Company’s proxy solicitation agent, Laurel Hill, toll-free in North America at 1.877.452.7184, outside North America at 1.416.304.0211, or by email at assistance@laurelhill.com.

 

About ProMIS Neurosciences Inc.

 

ProMIS Neurosciences Inc. is a development stage biotechnology corporation focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Multiple system atrophy (MSA). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform - ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. ProMIS is headquartered in Toronto, Ontario, Canada with offices in Cambridge, Massachusetts, U.S.A. ProMIS is listed on the Toronto Stock Exchange (“TSX”) under symbol PMN, and on the OTCQB Venture Market under symbol ARFXF.

 

To learn more, visit us at www.promisneurosciences.com, follow us on Twitter and LinkedIn

 

For Investor Relations please contact:

Alpine Equity Advisors

Nicholas Rigopulos, President

nick@alpineequityadv.com

Tel. 617 901-0785

 

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. Certain information in this news release constitutes forward-looking statements and forward-looking information (collectively, ‎‎"forward-looking information") within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", ‎‎"is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Specifically, this news release contains forward-looking information relating to the Meeting, future management of the Company and the potential benefits of targeting misfolded proteins. Statements containing forward-looking information are not historical facts but instead represent management's current expectations, estimates and projections regarding the future of our business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information. Important factors that could cause actual results and financial condition to differ materially from those indicated in the forward-looking information include, among others, the factors discussed throughout the "Risk Factors" section of the Company's most recently filed annual information form available on www.SEDAR.com. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update any forward-looking information, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.